These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35156138)

  • 21. [New antidiabetic drugs: current status and future prospects - a review of the literature].
    Baranowska A; Stefanowicz-Rutkowska M; Matuszewski W; Bandurska-Stankiewicz E
    Wiad Lek; 2018; 71(8):1588-1598. PubMed ID: 30684345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological management of type 2 diabetes mellitus: an update.
    El-Kaissi S; Sherbeeni S
    Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
    Tahrani AA; Barnett AH; Bailey CJ
    Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.
    Eckerle Mize DL; Salehi M
    Curr Diab Rep; 2013 Jun; 13(3):307-18. PubMed ID: 23479200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
    Hurren KM; Dunham MW
    Expert Opin Pharmacother; 2018 Jul; 19(10):1087-1095. PubMed ID: 29958007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 29. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G; Gra-Menendez S
    Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):15-25. PubMed ID: 24362783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
    Packer M
    J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
    DeFilippis EM; Givertz MM
    Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M; Shibasaki M; Echizen H; Kushiyama A
    PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.